gene editing
Mammoth Biosciences to Initiate IND-Enabling Studies in First CRISPR Candidate This Year
The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.
Vertex Appeals Ruling That Fertility Support for Casgevy Patients Would Violate Kickback Laws
A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.
Verve Advances Clinical Development Plans for Base-Editing Heart Disease Treatment
After VERVE-102 showed the ability to lower LDL-C and PCSK9 in the Heart-2 trial, the firm said it will advance the therapy to a Phase II study later this year.
Court Sides With HHS, Blocking Vertex Program to Cover Fertility Services for Patients on Casgevy
HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.
Verve Therapeutics to Kick off Base-Editing Cardiovascular Drug Phase I Trial in the US
The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.
Jan 14, 2025
Dec 11, 2024